Irradiation in the Local Control of Malignant Lymphoreticular Tumors (Non-Hodgkin's Malignant Lymphoma)

Cox, James D.; Koehl, Robert H.; Turner, Wesley D.; King, F. M.

doi:10.1148/112.1.179

Cited by 68 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient with primary bone involvement was treated with 44 Gy and was without in-field recurrence at the last follow-up (13 years). Some authors recommend a dose of 25-30 Gy for lymphomas < 2.5 cm [7] and higher doses (30-40 Gy) for lymphomas measuring > 3 cm or when there is an involvement of the bone or the brain [6,8,9]. In our group of patients, all in-field recurrences were observed in regions treated with a dose ≤ 26 Gy.…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Radiotherapy in stage I–III follicular non-Hodgkin lymphoma

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 87%

“…Kamath et al [5] suggested that 30 Gy given in 15-20 fractions is sufficient for most low-grade lymphomas. Cox et al [6] reported doses greater than 30 Gy are required to control lymphomas involving bone or brain. In the present study, only 1 patient presented with brain FL and 1 patient had primary bone involvement of the vertebral column.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy in stage I–III follicular non-Hodgkin lymphoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…This was first noted by Sagerman [19] whose patients failed local control and prolonged survival following doses below 3000 R. Cox [20] noted improved control in doses above 4500 cGy as did Berry [3] who reported two survivors at two years after 5000 cGy to 193 the whole brain. Loeffler [12] with the addition of chemotherapy noted four long term survivors.…”

Section: The Influence Of Dosementioning

confidence: 83%

“…Chamberlain at the University of California provided procarbazine (P) (60 mg/sq • m days [8][9][10][11][12][13][14][15][16][17][18][19][20][21], CCNU (C) (110 mg/sq • m on day 1), vincristine (V) (1.4mg/sq • m days 8, 29) in 6 weeks cycles after the completion of irradiation (5500-6100cGy) with concomitant hydroxyurea. Median survivals of 30 months (upper quartile 50 months) were noted.…”

Section: Chemotherapy Of Brain Lymphomamentioning

confidence: 99%

The therapy of primary brain lymphoma

Hochberg

Loeffler²,

Prados

1991

J Neuro-Oncol

View full text Add to dashboard Cite

Recommendations regarding the current therapy of primary brain lymphoma (NHL-CNS) take into account the occurrence of this tumor in immunocompetent and immunosuppressed hosts. Immunohistochemical evaluation of biopsy material or spinal fluid provides the diagnosis in 90% of patients. For the immunocompetent, pre-irradiation intra-venous or intra-arterial chemotherapy with Methotrexate alone or in combination with other agents is provided to treat tumor within multiple brain sites. Subarachnoid deposits are treated with Methotrexate by intrathecal administration. Radiation is provided after chemotherapy and for the treatment of vitreal/retinal deposits or symptomatic lesions within the spinal axis. The therapy of recurrent NHL-CNS makes use of intravenous Methotrexate or high dose Cytosine Arabinoside. Immunosuppressed patients respond to reduction of immunosuppressive medication. The therapy of NHL-CNS in the AIDS patient makes use of corticosteroids followed by cranial irradiation. A discussion of emerging trends in the therapy of NHL-CNS in the AIDS and non-AIDS population is provided.

show abstract

“…For intermediate/high-grade lymphoma, the radiation dose issue is less clear, but higher doses may be needed [17,29]. Besides, most of the dose-response analyses of lymphoma in the literature were performed in the era when patients received radiotherapy alone [4,12,28].…”

Section: Introductionmentioning

confidence: 99%

Analysis of Local Control in Patients with Non-Hodgkin’s Lymphoma According to the WHO Classification

et al. 2005

View full text Add to dashboard Cite

Purpose:To analyze the influence of radiotherapy doses, chemotherapy doses, and clinical parameters on in-field disease control to assess the optimal radiation doses for treatment of non-Hodgkin's lymphoma according to the newly proposed WHO classification. Patients and Methods: Subjects consisted of 35 extranodal marginal-zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) type, 75 diffuse large B-cell lymphomas (DLBCL), 14 follicular lymphomas, 17 extranodal natural killer (NK)/T-cell lymphomas, nasal type, eight unclassified peripheral T-cell lymphomas, four anaplastic large-cell lymphomas, T/null cell type, and five others. 59 patients received radiotherapy alone. 98 patients received CHOP, modified CHOP, or more intensive chemotherapy, and six patients were treated with other combination. Results: No patients with MALT lymphoma had in-field local recurrence. There were no recurrences in DLBCL patients who received chemotherapy in which the doses of adriamycin were > 200 mg/m 2 , nor in DLBCL patients who were treated with > 45 Gy. Only nine of 15 patients with T-cell lymphoma treated with ≤ 50 Gy and three of five patients treated with > 50 Gy had local control. The dose of adriamycin had no influence on local control of T-cell lymphoma. Conclusion: T/NK-cell lymphomas were more radioresistant than B-cell lymphomas. The prognosis for peripheral T/NK-cell lymphomas is poor even when treated by irradiation combined with chemotherapy. Analyse der lokalen Kontrolle beim Non-Hodgkin-Lymphom gemäß WHO-KlassifikationZiel: Untersuchung des Einflusses der Strahlungsdosis, Chemotherapie-Intensität und klinischer Parameter auf die Kontrolle lokalisierter Herde, um optimale Parameter für die Behandlung des Non-Hodgkin-Lymphoms gemäß der vor kurzem vorgeschlagenen WHO-Klassifikation zu ermitteln. Patienten und Methodik: In die Untersuchung einbezogen wurden 35 extranodale ("marginal-zone") B-Zell-Lymphome des Mukosa-assoziierten-Lymphom-(MALT-)Typs, 75 diffuse großzellige B-Zell-Lymphome (DLBCL), 14 follikuläre Lymphome, 17 extranodale Natürliche-Killer-(NK-)/T-Zell-Lymphome (Nasaltyp), 8 unklassifizierte periphere T-Zell-Lymphome, 4 anaplastische (großzellige) Lymphome (T/null-Zell-Typ) and 5 andere. 59 Patienten erhielten ausschließlich Strahlentherapie. 98 Patienten erhielten CHOP, CHOP modifiziert oder eine intensivierte Chemotherapie, und 6 Patienten wurden mit einer anderen Kombination behandelt. Ergebnisse: Bei keinem der MALT-Lymphom-Patienten kam es zu einem Lokalrezidiv. Rezidive traten weder bei DLBCL-Patienten auf, die Chemotherapie mit Adriamycin in Dosierungen > 200 mg/m 2 erhalten hatten, noch bei DLBCL-Patienten, die mit > 45 Gy behandelt worden waren. Nur bei 9 von 15 T-Zell-Lymphom-Patienten, die mit ≤ 50 Gy, und bei 3 von 5 Patienten die mit > 50 Gy behandelt worden waren, wurde eine lokale Kontrolle erreicht. Die Adriamycin-Dosis beeinflusste die lokale Kontrolle von T-ZellLymphomen nicht. Schlussfolgerungen: T/NK-Zell-Lymphome zeigten sich strahlungsresistenter als B-Zell-Lymphome. Die ...

show abstract

Irradiation in the Local Control of Malignant Lymphoreticular Tumors (Non-Hodgkin's Malignant Lymphoma)

Cited by 68 publications

References 17 publications

Radiotherapy in stage I–III follicular non-Hodgkin lymphoma

Radiotherapy in stage I–III follicular non-Hodgkin lymphoma

The therapy of primary brain lymphoma

Analysis of Local Control in Patients with Non-Hodgkin’s Lymphoma According to the WHO Classification

Contact Info

Product

Resources

About